Tumor-specific T-cell help is associated with improved survival in melanoma.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23864163.
- Also identified by DOI 10.1158/1078-0432.CCR-13-1349.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite success with immune checkpoint inhibitors, clinical benefit from cancer vaccines remains elusive. Combined targeting of melanoma-specific CD4(+) and CD8(+) T-lymphocyte epitopes was associated with improved survival compared with targeting either alone, or when a nonspecific helper epitope was used. We discuss the potential role of antigen-specific CD4 help.
Medical subject headings
- CD4-Positive T-Lymphocytes
- CD8-Positive T-Lymphocytes
- Cancer Vaccines
- Melanoma